Clot dissolution using fibrinolytic agents is a promising approach to the treatment of thromboembolic disease, particularly peripheral venous and arterial occlusion. In their present state of development, these agents are not recommended for general use in thrombosis or embolism in the cerebral or coronary circulations. Dosage units are still not standardized. The commercially available "fibrinolysins" are, in reality, combinations of plasmin (or fibrinolysin) and an activator of plasminogen (or profibrinolysin). Physicians must know the limitations of these preparations and the factors that alter doasage requirements.
The mechanism of renal autoregulation is unclear. The subject of the present investigation is the mechanism of autoregulation of blood flow in the int...
A case is reported of chronic massive thromboembolic occlusion of major pulmonary arterial branches successfully treated with embolectomy and endarter...
Links with this icon indicate that you are leaving a Bureau of Transportation
Statistics (BTS)/National Transportation Library (NTL)
Web-based service.
Thank you for visiting.
You are about to access a non-government link outside of
the U.S. Department of Transportation's National
Transportation Library.
Please note: While links to Web sites outside of DOT are
offered for your convenience, when you exit DOT Web sites,
Federal privacy policy and Section 508 of the Rehabilitation
Act (accessibility requirements) no longer apply. In
addition, DOT does not attest to the accuracy, relevance,
timeliness or completeness of information provided by linked
sites. Linking to a Web site does not constitute an
endorsement by DOT of the sponsors of the site or the
products presented on the site. For more information, please
view DOT's Web site linking policy.
To get back to the page you were previously viewing, click
your Cancel button.
United States Department of Transportation
[PDF-592.88 KB]
